NCT06993038PHASE4Recruiting

Adenosine vs Diltiazem for Treatment of SVT in the ED

Anne E. Zepeski

Start Date

8/1/2025

Completion Date

12/1/2027

Summary

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Eligibility Criteria

Age Range: 18 years to 100 years

Inclusion Criteria: 1. Adult patients (18 years and older) 2. Diagnosis of acute, stable SVT in the emergency department Exclusion Criteria: 1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting). 2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome 3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%) 4. Severe bronchoconstrictive lung disease 5. Prior hypersensitivity to study medication 6. Previously enrolled in pilot study 7. Pregnant 8. Incarcerated

Interventions

DRUG

adenosine

DRUG

diltiazem

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Supraventricular Tachycardia (SVT)

Locations

University of Iowa Health Care

Iowa City, Iowa 52242

United States